A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)

NCT00075218

Last updated date
Study Location
Pfizer Investigational Site
Duarte, California, 91010, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Gastrointestinal Stromal Tumor
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent

- Failed Gleevec treatment or intolerant to Gleevec therapy

Key

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or
investigational agent since the last dose of Gleevec

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Gastrointestinal Stromal TumorA Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
NCT00075218
  1. Duarte, California
  2. Los Angeles, California
  3. Los Angeles, California
  4. Pasadena, California
  5. Santa Monica, California
  6. Stanford, California
  7. Washington, District of Columbia
  8. Miami, Florida
  9. Tampa, Florida
  10. Park Ridge, Illinois
  11. Boston, Massachusetts
  12. Detroit, Michigan
  13. Minneapolis, Minnesota
  14. St. Louis, Missouri
  15. New York, New York
  16. New York, New York
  17. New York, New York
  18. Durham, North Carolina
  19. Cleveland, Ohio
  20. Columbus, Ohio
  21. Columubs, Ohio
  22. Portland, Oregon
  23. Philadelphia, Pennsylvania
  24. Nashville, Tennessee
  25. Seattle, Washington
  26. Seattle, Washington
  27. Madison, Wisconsin
  28. Garran, Australian Capital Territory
  29. Camperdown, New South Wales
  30. Randwick, New South Wales
  31. Auchenflower, Queensland
  32. Ashford, South Australia
  33. Bedford Park, South Australia
  34. East Melbourne, Victoria
  35. Leuven,
  36. Toronto, Ontario
  37. Montreal, Quebec
  38. Lyon,
  39. Marseille,
  40. VILLEJUIF Cedex,
  41. Aviano, PN
  42. Candiolo, Torino
  43. Bologna,
  44. Genova,
  45. Milano,
  46. Milano,
  47. Milano,
  48. Torino,
  49. Groningen, Gr
  50. Rotterdam, ZH
  51. Singapore,
  52. Singapore,
  53. Singapore,
  54. L'Hospitalet del Llobregat, Barcelona
  55. Barcelona,
  56. Madrid,
  57. Lausanne,
  58. Sutton, Surrey
  59. Leeds,
  60. London,
  61. Newcastle-Upon-Tyne,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Gastrointestinal Stromal TumorSafety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
NCT00372567
  1. Detroit, Michigan
  2. Farmington Hills, Michigan
  3. Creve Coeur, Missouri
  4. St. Louis, Missouri
  5. St. Peters, Missouri
  6. Philadelphia, Pennsylvania
  7. Goettingen,
  8. Hamburg,
  9. Lai Chi Kok, Kowloon
  10. Tuen Mun, New Territories
  11. Hong Kong,
  12. Bologna,
  13. Milano,
  14. San Giovanni Rotondo,
  15. Seoul,
  16. Seoul,
  17. Seoul,
  18. Barcelona,
  19. Valencia,
  20. Glasgow,
  21. Leeds,
  22. London,
  23. London,
  24. London,
  25. Manchester,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
Official Title  ICMJE A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Brief Summary A study to assess the safety and efficacy of SU11248 in patients with gastrointestinal stromal tumor (GIST) whose disease has failed imatinib therapy or who were intolerant to imatinib treatment.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Condition  ICMJE Gastrointestinal Stromal Tumor
Intervention  ICMJE
  • Drug: Placebo
    50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
  • Drug: SU011248
    50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
Study Arms  ICMJE
  • Placebo Comparator: B
    Intervention: Drug: Placebo
  • Active Comparator: A
    Intervention: Drug: SU011248
Publications * Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 Oct 14;368(9544):1329-38.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: August 31, 2009)
361
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE May 2008
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Key Inclusion Criteria:

  • Histologically-proven diagnosis of malignant GIST not amenable to surgery, radiation or combined modality treatment with curative intent
  • Failed Gleevec treatment or intolerant to Gleevec therapy

Key Exclusion Criteria:

  • Treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational agent since the last dose of Gleevec
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Belgium,   Canada,   France,   Italy,   Netherlands,   Singapore,   Spain,   Switzerland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00075218
Other Study ID Numbers  ICMJE A6181004
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer Inc
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date August 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP